BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 15596754)

  • 21. Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda.
    Abassi M; Morawski BM; Nakigozi G; Nakasujja N; Kong X; Meya DB; Robertson K; Gray R; Wawer MJ; Sacktor N; Boulware DR
    J Neurovirol; 2017 Jun; 23(3):369-375. PubMed ID: 27995575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
    Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
    Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical factors related to brain structure in HIV: the CHARTER study.
    Jernigan TL; Archibald SL; Fennema-Notestine C; Taylor MJ; Theilmann RJ; Julaton MD; Notestine RJ; Wolfson T; Letendre SL; Ellis RJ; Heaton RK; Gamst AC; Franklin DR; Clifford DB; Collier AC; Gelman BB; Marra C; McArthur JC; McCutchan JA; Morgello S; Simpson DM; Grant I;
    J Neurovirol; 2011 Jun; 17(3):248-57. PubMed ID: 21544705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.
    Spudich SS; Nilsson AC; Lollo ND; Liegler TJ; Petropoulos CJ; Deeks SG; Paxinos EE; Price RW
    BMC Infect Dis; 2005 Nov; 5():98. PubMed ID: 16266436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people.
    Vitiello B; Goodkin K; Ashtana D; Shapshak P; Atkinson JH; Heseltine PN; Eaton E; Heaton R; Lyman WD
    AIDS; 2007 Jul; 21(11):1415-22. PubMed ID: 17589187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals.
    Pérez-Santiago J; De Oliveira MF; Var SR; Day TRC; Woods SP; Gianella S; Mehta SR
    J Neurovirol; 2017 Apr; 23(2):283-289. PubMed ID: 27921220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children.
    McCoig C; Castrejón MM; Saavedra-Lozano J; Castaño E; Báez C; Lanier ER; Sáez-Llorens X; Ramilo O
    Pediatr Infect Dis J; 2004 Feb; 23(2):114-8. PubMed ID: 14872175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-associated dementia in older adults: clinical and tomographic aspects.
    Brito e Silva ET; Caixeta LF; Soares VL; Sagawa GR
    Int Psychogeriatr; 2011 Sep; 23(7):1061-9. PubMed ID: 21324232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
    Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
    J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals.
    De Luca A; Ciancio BC; Larussa D; Murri R; Cingolani A; Rizzo MG; Giancola ML; Ammassari A; Ortona L
    Neurology; 2002 Aug; 59(3):342-7. PubMed ID: 12177366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.
    Angel JB; High K; Rhame F; Brand D; Whitmore JB; Agosti JM; Gilbert MJ; Deresinski S
    AIDS; 2000 Mar; 14(4):387-95. PubMed ID: 10770541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion.
    Marcotte TD; Deutsch R; McCutchan JA; Moore DJ; Letendre S; Ellis RJ; Wallace MR; Heaton RK; Grant I;
    Arch Neurol; 2003 Oct; 60(10):1406-12. PubMed ID: 14568811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
    Valle M; Price RW; Nilsson A; Heyes M; Verotta D
    Brain; 2004 May; 127(Pt 5):1047-60. PubMed ID: 15013955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
    Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
    J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection.
    Mellgren A; Price RW; Hagberg L; Rosengren L; Brew BJ; Gisslén M
    Neurology; 2007 Oct; 69(15):1536-41. PubMed ID: 17923616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.